Information about Trandolapril
Trandolapril is an oral angiotensin-converting enzyme (ACE) inhibitor used in the therapy of hypertension and heart failure.
Liver safety of Trandolapril
Trandolapril is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of acute liver injury.
Mechanism of action of Trandolapril
Trandolapril (tran dol' a pril) is an ACE inhibitor which is approved for use alone and in combination with other agents in the therapy of hypertension and congestive heart failure. Like other ACE inhibitors, trandolapril inhibits the conversion of angiotensin I, a relatively inactive molecule, to angiotensin II which is the major mediator of vasoconstriction and volume expansion induced by the renin-angiotensin system. Other host enzymes besides that which converts angiotensin I to II may be inhibited as well, which may account for some of the side effects of the ACE inhibitors.
FDA approval information for Trandolapril
Trandolapril was approved for use in the United States in 1996 and is available in 1, 2 and 4 mg tablets in generic forms and under the trade name Mavik.
Dosage and administration for Trandolapril
The typical daily dose in adults is 2 to 4 mg in one or two divided doses which is administered long term. Trandolapril is also available in fixed dose combinations with verapamil (Tarka and generics).
Side effects of Trandolapril
Common side effects include dizziness, fatigue, headache, cough, gastrointestinal upset and skin rash.
Common ACE inhibitors include the following: